Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.
Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.
Compton
Leigh A
LA
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Hiebert
Scott W
SW
D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D056985:Nuclear Receptor Co-Repressor 2 / Q000235:genetics / Q000502:physiology / Q000627:therapeutic use*; D057285:Precision Medicine / Q000639:trends; D051560:Proto-Oncogene Proteins c-bcl-6
C084103:BCL6 protein, human; D004268:DNA-Binding Proteins; C539130:NCOR2 protein, human; D056985:Nuclear Receptor Co-Repressor 2; D051560:Proto-Oncogene Proteins c-bcl-6